Tecentriq
Researchers aim to validate the AI tool SCORPIO in prospective studies and eventually seek FDA clearance to sell it as a commercial tool in the US.
Roche Reports 5 Percent CER Growth in Pharmaceutical Sales Driven by Strong Phesgo Uptake
In the first half of the year, sales of the injectable formulation of HER2-targeted agent grew 60 percent at CER, compared to H1 2023.
Nykode Therapeutics Evaluating Cancer Vaccine With Tecentriq in HPV16-Positive Cervical Cancer
The double-blind trial will determine whether the cancer vaccine VB10.16 alone or combined with Tecentriq is more effective.
Gritstone Bio Eyes Pivotal Trial for Personalized Cancer Vaccine as Early ctDNA Endpoint Disappoints
Premium
Granite didn't improve molecular response, but the firm is talking up what it sees as other positive signs for its bespoke vaccine in MSS colorectal cancer.
Nykode Therapeutics Cleared to Begin Phase II Trial of Vaccine, Tecentriq in Cervical Cancer
The trial, slated to begin in Q4, will involve patients with HPV16-positive, PD-L1-positive, recurrent or metastatic cervical cancer.